Company Analysis Halozyme Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (33.21%) is higher than the sector average (-29.77%).
- The company's current efficiency (ROE=336%) is higher than the sector average (ROE=9.61%)
Disadvantages
- Price (49.3 $) is higher than fair price (32.99 $)
- Dividends (0%) are below the sector average (0.5491%).
- Current debt level 88.36% has increased over 5 years from 28.71%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Halozyme Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -8.4% | -16.4% | 1.7% |
| 90 days | -10.5% | -46.1% | 6.1% |
| 1 year | 33.2% | -29.8% | 33.5% |
HALO vs Sector: Halozyme Therapeutics, Inc. has outperformed the "Healthcare" sector by 62.97% over the past year.
HALO vs Market: Halozyme Therapeutics, Inc. has underperformed the market marginally by -0.3114% over the past year.
Stable price: HALO is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: HALO with weekly volatility of 0.6386% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (49.3 $) is higher than the fair price (32.99 $).
Price is higher than fair: The current price (49.3 $) is 33.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (17.7) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (17.7) is lower than that of the market as a whole (48.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (59.49) is higher than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (59.49) is higher than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.01) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (6.01) is lower than that of the market as a whole (10.14).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.07) is higher than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (15.07) is lower than that of the market as a whole (19.1).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -98% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-98%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (336%) is higher than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (336%) is higher than that of the market as a whole (10.87%).
5.5. ROA
ROA vs Sector: The company's ROA (16.25%) is higher than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (16.25%) is higher than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (42.26%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (42.26%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5491%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (4.79%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 09.10.2024 | HELEN TORLEY Officer |
Purchase | 52.58 | 525 800 | 10 000 |
| 08.10.2024 | HELEN TORLEY Officer |
Purchase | 54 | 540 000 | 10 000 |
| 26.09.2024 | HELEN TORLEY Officer |
Purchase | 56.1 | 561 000 | 10 000 |
| 25.09.2024 | HELEN TORLEY Officer |
Purchase | 56.34 | 563 400 | 10 000 |
| 24.09.2024 | HELEN TORLEY Officer |
Purchase | 58.21 | 582 100 | 10 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
